GI cancer-net 海外学会速報レポート 2018.1. San Francisco

2018年1月18日~20日に米国サンフランシスコにて開催された2018年 消化器癌シンポジウム(2018 Gastrointestinal Cancers Symposium)より、大腸癌や胃癌、肝細胞癌などの注目演題のレポートをお届けします。演題レポートの冒頭には“Expert's view”として、臨床研究の第一線で活躍する監修ドクターのコメントを掲載しています。



  • 2018年02月01日 #734#745 を公開しました。
  • 2018年01月31日 #206#557 を公開しました。
  • 2018年01月30日 #1#4#5 を公開しました。
  • 2018年01月29日 #205#207 を公開しました。
  • 2018年01月24日 サイト、Live Short Cuts を公開しました。



Abstract #1

Long-term outcome of a randomized phase III trial exploring the significance of extensive intraoperative peritoneal lavage in addition to standard treatment for ≥T3 resectable gastric cancer: CCOG1102

Daishi Morimoto, et al.

Abstract #4

Intraperitoneal immunotherapy with the bispecific anti-EpCAM x anti-CD3 directed antibody catumaxomab for patients with peritoneal carcinomatosis from gastric cancer: Final results of a randomized phase II AIO trial

Florian Lordick, et al.

Abstract #5

RAINFALL: A randomized, double-blind, placebo-controlled phase 3 study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma

Charles S. Fuchs, et al.

Abstract #205

Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer (JCOG1113)

Chigusa Morizane, et al.

Abstract #206

Randomized, open label, multicenter, phase II trial of Transcatheter Arterial Chemoembolization (TACE) Therapy In Combination with Sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial

Masatoshi Kudo, et al.

Abstract #207

Cabozantinib versus placebo in patients with advanced hepatocellular carcinoma who have received prior sorafenib: results from the randomized phase 3 CELESTIAL trial

Ghassan K. Abou-Alfa, et al.

Abstract #557

REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan.

Kohei Shitara, et al.


Abstract #734

A randomized phase II study of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab for previously untreated, liver-limited metastatic colorectal cancer that is unsuitable for resection (ATOM trial)

Hiroyuki Uetake, et al.

Abstract #745

Panitumumab versus cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer with prior bevacizumab therapy: A combined analysis of individual patient data from ASPECCT and WJOG6510G

Hiroya Taniguchi, et al.